Literature DB >> 10091414

Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes.

M Sampietro1, A Iolascon.   

Abstract

BACKGROUND AND
OBJECTIVE: Crigler-Najjar syndromes type I and II and Gilbert's syndrome are familial unconjugated hyperbilirubinemias caused by genetic lesions involving a single complex locus encoding for bilirubin-UDP-glucuronosyltransferase which is involved in the detoxification of bilirubin by conjugation with glucuronic acid. Over the last few years a number of different mutations affecting this gene have been characterized. The aim of this work is to review the molecular pathology of Crigler-Najjar and Gilbert's syndromes, to discuss its impact on the clinical and genetic classification of these conditions, and on the diagnostic evaluation of clinical pictures associated with unconjugated hyperbilirubinemia. EVIDENCE AND INFORMATION SOURCES: The authors of the present review are involved in the clinical management of patients with familial unconjugated hyperbilirubinemia as well as in the characterization of its molecular bases. Evidence from journal articles covered by the Science Citation Index and Medline has been reviewed and collated with personal data and experience. STATE OF THE ART AND PERSPECTIVES: It has been known for many years that mild to severe deficiency of bilirubin UDP-glucuronosyltransferase in the liver is the cause of two types of familial unconjugated hyperbilirubinemia, Crigler-Najjar syndromes I and II, and Gilbert's syndrome. Since the characterization of the gene encoding for bilirubin UDP-glucuronosyltransferase, a number of mutations affecting the expression of this gene have been identified. These mutations can be classified into three groups: mutations which result in a reduced production of a normal enzyme; mutations which give rise to the synthesis of a structurally abnormal and dysfunctional enzyme; mutations which completely abolish the expression of the affected allele. The combination of mutations affecting the coding region of the gene and of promoter mutations which reduce the expression of the gene accounts for the wide clinical spectrum of familial unconjugated hyperbilirubinemias, ranging from the clinically negligible Gilbert's syndrome to the severe and often fatal Crigler-Najjar type I syndrome. A better understanding of the genetics of these conditions and the availability of molecular diagnosis will improve the diagnostic efficiency and afford better informed genetic counseling, not only for Crigler-Najjar and Gilbert's syndromes, but also for several acquired conditions characterized by unconjugated hyperbilirubinemia.

Entities:  

Mesh:

Year:  1999        PMID: 10091414

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  12 in total

1.  The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients.

Authors:  Suad AlFadhli; Hassan Al-Jafer; Mays Hadi; Mashael Al-Mutairi; Rasheeba Nizam
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

Review 2.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

3.  Bile bilirubin pigment analysis in disorders of bilirubin metabolism in early infancy.

Authors:  W S Lee; P J McKiernan; S V Beath; M A Preece; D Baty; D A Kelly; B Burchell; D J Clarke
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791

4.  Exome sequencing and arrayCGH detection of gene sequence and copy number variation between ILS and ISS mouse strains.

Authors:  Laura Dumas; C Michael Dickens; Nathan Anderson; Jonathan Davis; Beth Bennett; Richard A Radcliffe; James M Sikela
Journal:  Mamm Genome       Date:  2014-02-20       Impact factor: 2.957

5.  Case Study 6: Deconvoluting Hyperbilirubinemia-Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A1, MRP2, or OATP1B1 in Drug Development.

Authors:  Ian Templeton; Gary Eichenbaum; Rucha Sane; Jin Zhou
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects.

Authors:  Kara R Vogel; Andrew A Kennedy; Luke A Whitehouse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2013-10-02       Impact factor: 4.982

7.  A case of concomitant Gilbert's syndrome and hereditary spherocytosis.

Authors:  Hee Jung Lee; Hee Seok Moon; Eaum Seok Lee; Seok Hyun Kim; Jae Kyu Sung; Byung Seok Lee; Hyun Yong Jeong; Heon Young Lee; Young Jae Eu
Journal:  Korean J Hepatol       Date:  2010-09

Review 8.  Hb E/beta-thalassaemia: a common & clinically diverse disorder.

Authors:  Nancy F Olivieri; Zahra Pakbaz; Elliott Vichinsky
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

9.  Crigler-Najjar syndrome type II in a Chinese boy resulting from three mutations in the bilirubin uridine 5'-diphosphate-glucuronosyltransferase (UGT1A1) gene and a family genetic analysis.

Authors:  Bixia Zheng; Guorui Hu; Jin Yu; Zhifeng Liu
Journal:  BMC Pediatr       Date:  2014-10-15       Impact factor: 2.125

10.  A GWAS Study on Liver Function Test Using eMERGE Network Participants.

Authors:  Bahram Namjou; Keith Marsolo; Todd Lingren; Marylyn D Ritchie; Shefali S Verma; Beth L Cobb; Cassandra Perry; Terrie E Kitchner; Murray H Brilliant; Peggy L Peissig; Kenneth M Borthwick; Marc S Williams; Jane Grafton; Gail P Jarvik; Ingrid A Holm; John B Harley
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.